OncoMatch

OncoMatch/Clinical Trials/NCT06363006

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

Is NCT06363006 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies TKI+Cardunilimab for hepatocellular carcinoma.

Phase 1RecruitingPeking Union Medical College HospitalNCT06363006Data as of Jun 2026Location: China

Treatment: TKI+CardunilimabThe goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma. The main questions it aims to answer are: * Objective response rate (ORR) for evaluation * Disease Control Rate (DCR); Duration of relief (DoR); Progression free survival (PFS); Total survival time (OS); Safety。

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

TKI+Cardunilimab

Cancer type

Hepatocellular Carcinoma

Disease stage

Required: Stage BCLC STAGE C, STAGE B THAT PROGRESSES IRREMEDIABLY AFTER SURGERY AND/OR LOCAL TREATMENT (BCLC)

Barcelona Clinic Liver Cancer (BCLC) stage C; It is not suitable for radical surgery and/or local treatment or stage B that progresses irremediably after surgery and/or local treatment.

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Prior therapy

Min 1 prior line

Must have received: systemic antitumor therapy

Progression or intolerance after receiving at least one systemic antitumor therapy for hepatocellular carcinoma prior to initial administration

Cannot have received: liver transplantation

History of liver transplantation.

Lab requirements

Liver function

child-pugh level a

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06363006 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior liver transplantation disqualifies patients from enrollment.

What disease stage is eligible?

Stage BCLC STAGE C or STAGE B THAT PROGRESSES IRREMEDIABLY AFTER SURGERY AND/OR LOCAL TREATMENT is required.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify